BNTX catalyst calendar

BioNTech SE

Upcoming catalysts
28
Cash runway
Cash generating
Cash & investments
EUR 14877M
Phase 3 programs
21

BioNTech SE is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).

The next scheduled catalyst is A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions on October 15, 2026. There are 28 upcoming events on record.

BioNTech SE generates cash from operations, so a burn-based runway figure does not apply.

Across 43 concluded trials, 81% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
October 15, 2026 A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions Trial Milestone Phase 1
November 15, 2026 A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIV Trial Milestone Phase 1
November 15, 2026 A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer Trial Milestone Phase 2
April 21, 2027 A Study of COVID-19 Vaccine(s) in Children and Adults Trial Milestone Phase 3
June 15, 2027 Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy Trial Milestone Phase 2
June 15, 2027 A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa Trial Milestone Phase 2
August 20, 2027 A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age Trial Milestone Phase 4
November 15, 2027 A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors Trial Milestone Phase 1/Phase 2
December 15, 2027 A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer Trial Milestone Phase 2
January 15, 2028 A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma Trial Milestone Phase 2
February 15, 2028 A Clinical Trial to Look at the Safety and Immune Responses of the RNA-based Vaccine BNT168 in Adults Living With or Without HIV Trial Milestone Phase 1
March 15, 2028 A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors Trial Milestone Phase 1/Phase 2
March 15, 2028 A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer Trial Milestone Phase 3
August 15, 2028 Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy Trial Milestone Phase 2
August 15, 2028 A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 Trial Milestone Phase 2/Phase 3
September 15, 2028 A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer Trial Milestone Phase 1/Phase 2
October 15, 2028 Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment Trial Milestone Phase 2
November 15, 2028 A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC) Trial Milestone Phase 1/Phase 2
January 15, 2029 Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer Trial Milestone Phase 2/Phase 3
April 15, 2029 Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer Trial Milestone Phase 3
August 15, 2029 A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer Trial Milestone Phase 1/Phase 2
December 15, 2029 ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer Trial Milestone Phase 3
February 15, 2030 Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer Trial Milestone Phase 1
May 15, 2030 A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9 Trial Milestone Phase 1/Phase 2
October 15, 2030 Early-phase Trial to Assess the Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors Trial Milestone Phase 1/Phase 2
December 15, 2030 A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer Trial Milestone Phase 1/Phase 2
February 15, 2031 A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer Trial Milestone Phase 3
April 15, 2031 Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors Trial Milestone Phase 1/Phase 2

Track BNTX alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open BNTX in the tracker

Recent history

DateEventTypePhase
October 13, 2026 6-K filed: Foreign issuer report Filing —
September 18, 2026 6-K filed: Foreign issuer report Filing —
September 14, 2026 6-K filed: Foreign issuer report Filing —
August 28, 2026 6-K filed: Foreign issuer report Filing —
August 27, 2026 6-K filed: Foreign issuer report Filing —
August 20, 2026 6-K filed: Foreign issuer report Filing —
August 18, 2026 Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors Trial Milestone Phase 1
August 4, 2026 6-K filed: Foreign issuer report Filing —
August 4, 2026 6-K filed: Foreign issuer report Filing —
August 3, 2026 6-K filed: Foreign issuer report Filing —
July 31, 2026 A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age Trial Milestone Phase 3
July 30, 2026 Results filed (20-F/A) Earnings —
July 29, 2026 6-K filed: Foreign issuer report Filing —
July 24, 2026 A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19 Trial Milestone Phase 3
July 10, 2026 A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children Trial Milestone Phase 3
June 8, 2026 6-K filed: Foreign issuer report Filing —
June 1, 2026 6-K filed: Foreign issuer report Filing —
May 22, 2026 6-K filed: Foreign issuer report Filing —
May 15, 2026 6-K filed: Foreign issuer report Filing —
May 7, 2026 6-K filed: Foreign issuer report Filing —
May 5, 2026 6-K filed: Foreign issuer report Filing —
May 5, 2026 6-K filed: Foreign issuer report Filing —
May 1, 2026 A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years Trial Milestone Phase 3
April 13, 2026 6-K filed: Foreign issuer report Filing —
April 2, 2026 6-K filed: Foreign issuer report Filing —
April 1, 2026 Results filed (20-F/A) Earnings —
March 24, 2026 6-K filed: Foreign issuer report Filing —
March 12, 2026 Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers Trial Milestone Phase 1/Phase 2
March 10, 2026 6-K filed: Foreign issuer report Filing —
March 10, 2026 6-K filed: Foreign issuer report Filing —

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.